Genfit S.A. (GNFT) NASDAQ
8.95
+0.35(+4.07%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Genfit S.A.
Sector
Healthcare
Industry
Biotechnology
Employees
180
First IPO Date
March 27, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Pascal Prigent | Chief Executive Officer | 718,470 | 1968 |
| Jean-Francois Mouney | Co-Founder & Chairman of the Board | 441,579 | 1955 |
| Sakina Sayah-Jeanne | Chief Scientific Officer | 798,270 | 1972 |
| Jean-Christophe Marcoux | Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG | 0 | 1977 |
| Laurent Lannoo | Corporate Secretary & Director of Legal Affairs | 0 | 1970 |
| Pascal Caisey | Chief Operating Officer | 0 | 1968 |
| Thomas Baetz | Chief Financial Officer | 0 | 1974 |
| Emilie Desodt | Executive Vice President of Human Resources | 0 | 1983 |
| Stefanie Magner | Chief Compliance Officer & Executive Vice President of International Legal Affairs | 0 | 1981 |
| Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board | 0 | 1963 |
Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
